Literature DB >> 27351677

Acupuncture for the prevention of episodic migraine.

Klaus Linde1, Gianni Allais, Benno Brinkhaus, Yutong Fei, Michael Mehring, Emily A Vertosick, Andrew Vickers, Adrian R White.   

Abstract

BACKGROUND: Acupuncture is often used for migraine prevention but its effectiveness is still controversial. We present an update of our Cochrane review from 2009.
OBJECTIVES: To investigate whether acupuncture is a) more effective than no prophylactic treatment/routine care only; b) more effective than sham (placebo) acupuncture; and c) as effective as prophylactic treatment with drugs in reducing headache frequency in adults with episodic migraine. SEARCH
METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL: 2016, issue 1); MEDLINE (via Ovid, 2008 to January 2016); Ovid EMBASE (2008 to January 2016); and Ovid AMED (1985 to January 2016). We checked PubMed for recent publications to April 2016. We searched the World Health Organization (WHO) Clinical Trials Registry Platform to February 2016 for ongoing and unpublished trials. SELECTION CRITERIA: We included randomized trials at least eight weeks in duration that compared an acupuncture intervention with a no-acupuncture control (no prophylactic treatment or routine care only), a sham-acupuncture intervention, or prophylactic drug in participants with episodic migraine. DATA COLLECTION AND ANALYSIS: Two reviewers checked eligibility; extracted information on participants, interventions, methods and results, and assessed risk of bias and quality of the acupuncture intervention. The primary outcome was migraine frequency (preferably migraine days, attacks or headache days if migraine days not measured/reported) after treatment and at follow-up. The secondary outcome was response (at least 50% frequency reduction). Safety outcomes were number of participants dropping out due to adverse effects and number of participants reporting at least one adverse effect. We calculated pooled effect size estimates using a fixed-effect model. We assessed the evidence using GRADE and created 'Summary of findings' tables. MAIN
RESULTS: Twenty-two trials including 4985 participants in total (median 71, range 30 to 1715) met our updated selection criteria. We excluded five previously included trials from this update because they included people who had had migraine for less than 12 months, and included five new trials. Five trials had a no-acupuncture control group (either treatment of attacks only or non-regulated routine care), 15 a sham-acupuncture control group, and five a comparator group receiving prophylactic drug treatment. In comparisons with no-acupuncture control groups and groups receiving prophylactic drug treatment, there was risk of performance and detection bias as blinding was not possible. Overall the quality of the evidence was moderate. Comparison with no acupunctureAcupuncture was associated with a moderate reduction of headache frequency over no acupuncture after treatment (four trials, 2199 participants; standardised mean difference (SMD) -0.56; 95% CI -0.65 to -0.48); findings were statistically heterogeneous (I² = 57%; moderate quality evidence). After treatment headache frequency at least halved in 41% of participants receiving acupuncture and 17% receiving no acupuncture (pooled risk ratio (RR) 2.40; 95% CI 2.08 to 2.76; 4 studies, 2519 participants) with a corresponding number needed to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 6); there was no indication of statistical heterogeneity (I² = 7%; moderate quality evidence). The only trial with post-treatment follow-up found a small but significant benefit 12 months after randomisation (RR 2.16; 95% CI 1.35 to 3.45; NNT 7; 95% 4 to 25; 377 participants, low quality evidence). Comparison with sham acupunctureBoth after treatment (12 trials, 1646 participants) and at follow-up (10 trials, 1534 participants), acupuncture was associated with a small but statistically significant frequency reduction over sham (moderate quality evidence). The SMD was -0.18 (95% CI -0.28 to -0.08; I² = 47%) after treatment and -0.19 (95% CI -0.30 to -0.09; I² = 59%) at follow-up. After treatment headache frequency at least halved in 50% of participants receiving true acupuncture and 41% receiving sham acupuncture (pooled RR 1.23, 95% CI 1.11 to 1.36; I² = 48%; 14 trials, 1825 participants) and at follow-up in 53% and 42%, respectively (pooled RR 1.25, 95% CI 1.13 to 1.39; I² = 61%; 11 trials, 1683 participants; moderate quality evidence). The corresponding NNTBs are 11 (95% CI 7.00 to 20.00) and 10 (95% CI 6.00 to 18.00), respectively. The number of participants dropping out due to adverse effects (odds ratio (OR) 2.84; 95% CI 0.43 to 18.71; 7 trials, 931 participants; low quality evidence) and the number of participants reporting adverse effects (OR 1.15; 95% CI 0.85 to 1.56; 4 trials, 1414 participants; moderate quality evidence) did not differ significantly between acupuncture and sham groups. Comparison with prophylactic drug treatmentAcupuncture reduced migraine frequency significantly more than drug prophylaxis after treatment ( SMD -0.25; 95% CI -0.39 to -0.10; 3 trials, 739 participants), but the significance was not maintained at follow-up (SMD -0.13; 95% CI -0.28 to 0.01; 3 trials, 744 participants; moderate quality evidence). After three months headache frequency at least halved in 57% of participants receiving acupuncture and 46% receiving prophylactic drugs (pooled RR 1.24; 95% CI 1.08 to 1.44) and after six months in 59% and 54%, respectively (pooled RR 1.11; 95% CI 0.97 to 1.26; moderate quality evidence). Findings were consistent among trials with I² being 0% in all analyses. Trial participants receiving acupuncture were less likely to drop out due to adverse effects (OR 0.27; 95% CI 0.08 to 0.86; 4 trials, 451 participants) and to report adverse effects (OR 0.25; 95% CI 0.10 to 0.62; 5 trials 931 participants) than participants receiving prophylactic drugs (moderate quality evidence). AUTHORS'
CONCLUSIONS: The available evidence suggests that adding acupuncture to symptomatic treatment of attacks reduces the frequency of headaches. Contrary to the previous findings, the updated evidence also suggests that there is an effect over sham, but this effect is small. The available trials also suggest that acupuncture may be at least similarly effective as treatment with prophylactic drugs. Acupuncture can be considered a treatment option for patients willing to undergo this treatment. As for other migraine treatments, long-term studies, more than one year in duration, are lacking.

Entities:  

Mesh:

Year:  2016        PMID: 27351677      PMCID: PMC4977344          DOI: 10.1002/14651858.CD001218.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  97 in total

1.  A quantification of the placebo response in migraine prophylaxis.

Authors:  P-H M van der Kuy; J J H M Lohman
Journal:  Cephalalgia       Date:  2002-05       Impact factor: 6.292

2.  Acupuncture for migraine prophylaxis: a randomized controlled trial.

Authors:  Ying Li; Hui Zheng; Claudia M Witt; Stephanie Roll; Shu-guang Yu; Jie Yan; Guo-jie Sun; Ling Zhao; Wen-jing Huang; Xiao-rong Chang; Hong-xing Zhang; De-jun Wang; Lei Lan; Ran Zou; Fan-rong Liang
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

3.  Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial.

Authors:  C-P Yang; M-H Chang; P-E Liu; T-C Li; C-L Hsieh; K-L Hwang; H-H Chang
Journal:  Cephalalgia       Date:  2011-10-21       Impact factor: 6.292

4.  [Body acupuncture combined with auricular acupressure for menstrual headache: a randomized controlled clinical trial].

Authors:  Li-hong Sun; Xin-hua Li; Wen-li Li; Li Liu; Hong-li Ma; Yu-lei Liang
Journal:  Zhen Ci Yan Jiu       Date:  2015-02

Review 5.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

6.  [Use and acceptance of classical natural and alternative medicine in Germany--findings of a representative population-based survey].

Authors:  U Härtel; E Volger
Journal:  Forsch Komplementarmed Klass Naturheilkd       Date:  2004-12

Review 7.  Efficacy of biofeedback for migraine: a meta-analysis.

Authors:  Yvonne Nestoriuc; Alexandra Martin
Journal:  Pain       Date:  2006-11-02       Impact factor: 6.961

Review 8.  Acupuncture--self-appraisal and the reward system.

Authors:  Thomas Lundeberg; Iréne Lund; Jan Näslund
Journal:  Acupunct Med       Date:  2007-09       Impact factor: 2.267

9.  Health economic evaluation of acupuncture along meridians for treating migraine in China: results from a randomized controlled trial.

Authors:  Zhu-qing Deng; Hui Zheng; Ling Zhao; Si-yuan Zhou; Ying Li; Fan-rong Liang
Journal:  BMC Complement Altern Med       Date:  2012-06-14       Impact factor: 3.659

10.  Acupuncture as prophylaxis for menstrual-related migraine: study protocol for a multicenter randomized controlled trial.

Authors:  Xiao-Zhe Zhang; Lei Zhang; Jia Guo; Lin Zeng; Yi Yang; Tao Zhang; Guang-Xia Shi; Hui-Lin Liu; Lin-Peng Wang
Journal:  Trials       Date:  2013-11-06       Impact factor: 2.279

View more
  58 in total

1.  Integration of white matter network is associated with interindividual differences in psychologically mediated placebo response in migraine patients.

Authors:  Jixin Liu; Shaohui Ma; Junya Mu; Tao Chen; Qing Xu; Wanghuan Dun; Jie Tian; Ming Zhang
Journal:  Hum Brain Mapp       Date:  2017-07-21       Impact factor: 5.038

2.  Migraine management: beyond pills.

Authors:  Benjamin R Wakerley; Sarah Davies
Journal:  Br J Gen Pract       Date:  2018-10       Impact factor: 5.386

3.  Cochrane reviews on acupuncture therapy for pain: A snapshot of the current evidence.

Authors:  Arya Nielsen; L Susan Wieland
Journal:  Explore (NY)       Date:  2019-09-12       Impact factor: 1.775

4.  Acupuncture Resolves Persistent Pain and Neuroinflammation in a Mouse Model of Chronic Overlapping Pain Conditions.

Authors:  Seungtae Kim; Xin Zhang; Sandra C O'Buckley; Mary Cooter; Jongbae J Park; Andrea G Nackley
Journal:  J Pain       Date:  2018-07-04       Impact factor: 5.820

5.  Brain structural properties predict psychologically mediated hypoalgesia in an 8-week sham acupuncture treatment for migraine.

Authors:  Jixin Liu; Junya Mu; Qianqian Liu; Wanghuan Dun; Ming Zhang; Jie Tian
Journal:  Hum Brain Mapp       Date:  2017-06-13       Impact factor: 5.038

6.  Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews.

Authors:  L Susan Wieland; Brian M Berman; Douglas G Altman; Jürgen Barth; Lex M Bouter; Christopher R D'Adamo; Klaus Linde; David Moher; C Daniel Mullins; Shaun Treweek; Sean Tunis; Danielle A van der Windt; Merrick Zwarenstein; Claudia Witt
Journal:  J Clin Epidemiol       Date:  2017-02-07       Impact factor: 6.437

Review 7.  Acupuncture for the prevention of tension-type headache.

Authors:  Klaus Linde; Gianni Allais; Benno Brinkhaus; Yutong Fei; Michael Mehring; Byung-Cheul Shin; Andrew Vickers; Adrian R White
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

Review 8.  Behavioral Treatments for Post-Traumatic Headache.

Authors:  Felicia Fraser; Yuka Matsuzawa; Yuen Shan Christine Lee; Mia Minen
Journal:  Curr Pain Headache Rep       Date:  2017-05

9.  Integrated miRNA-seq analysis reveals the molecular mechanism underlying the effect of acupuncture on endometrial receptivity in patients undergoing fertilization: embryo transplantation.

Authors:  Yanyun Mu; Qian Li; Jie Cheng; Jie Shen; Xun Jin; Zhengyun Xie; Zhao Gao; Wenjing Zhang; Qixin Hua; Liangjun Xia; Youling Gao; Youbing Xia
Journal:  3 Biotech       Date:  2019-11-27       Impact factor: 2.406

10.  Scientific Knowledge Graph of Acupuncture for Migraine: A Bibliometric Analysis from 2000 to 2019.

Authors:  Yanqing Zhao; Li Huang; Meijuan Liu; Han Gao; Wentao Li
Journal:  J Pain Res       Date:  2021-06-30       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.